Brensocatib Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10mg, 25mg

Reference Brands: Brinsupri (USA/EU)

Category: Respiratory Disorder

Brensocatib (brand name Brinsupri) is an orally-administered, once-daily small-molecule inhibitor of dipeptidyl peptidase 1 (DPP1), which in turn reduces activation of neutrophil serine proteases responsible for airway inflammation and tissue damage in chronic lung disease. It is indicated for treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older, representing the first therapy specifically approved for this condition. In clinical trials, brensocatib reduced the annual rate of disease exacerbations and slowed lung function decline. Being the first in its class, it offers a novel mechanism targeting neutrophil-driven inflammation rather than purely the infection component. Brensocatib is available in Tablets and strengths such as 10mg, 25mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Brensocatib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Brensocatib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.